` 3320 (China Resources Pharmaceutical Group Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

3320
vs
Hang Seng (Hong Kong)

Over the past 12 months, has underperformed Hang Seng (Hong Kong), delivering a return of -8% compared to the Hang Seng (Hong Kong)'s 26% growth.

Stocks Performance
3320 vs Hang Seng (Hong Kong)

Loading
3320
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com

Performance Gap
3320 vs Hang Seng (Hong Kong)

Loading

Over the past 12 months, has underperformed Hang Seng (Hong Kong) by 34.04%.

3320
Hang Seng (Hong Kong)
Difference
www.alphaspread.com

Performance By Year
3320 vs Hang Seng (Hong Kong)

Loading
3320
Hang Seng (Hong Kong)
Add Stock

Competitors Performance
China Resources Pharmaceutical Group Ltd vs Peers

Hang Seng (Hong Kong)
3320
LLY
JNJ
NOVO B
ROG
Add Stock

China Resources Pharmaceutical Group Ltd
Glance View

Market Cap
32.4B HKD
Industry
Pharmaceuticals

In the vast and dynamic landscape of China's healthcare sector, China Resources Pharmaceutical Group Ltd. has emerged as a formidable player. Born from the rich heritage of its parent conglomerate, China Resources Holdings, the company weaves together a complex tapestry of pharmaceutical manufacturing, distribution, and retail operations. Its diversified operations ensure that it maintains a robust footprint across the entire pharmaceutical value chain. The company's manufacturing arm is a powerhouse, producing a vast array of products, including traditional Chinese medicine and modern pharmaceuticals, catering to the diverse needs of health consumers in China and beyond. Leveraging its extensive industry expertise and a deep understanding of the local market, China Resources Pharmaceutical crafts products that blend innovation with time-honored traditions, effectively meeting the growing demands for quality healthcare solutions. On the distribution and retail front, China Resources Pharmaceutical Group employs its extensive and well-integrated network to efficiently channel its products across the nation. The strategic positioning of its distribution centers enables it to serve hundreds of thousands of pharmacies, hospitals, and healthcare institutions, ensuring broad accessibility. Retail operations round out the company's comprehensive approach, with a wide-reaching chain of drugstores under its banner offering not only medicinal products but also healthcare services. This holistic business model not only diversifies revenue streams but also strengthens the company's ability to weather industry shifts, making it a resilient entity in the ever-evolving pharmaceutical and healthcare milieu. Through its multifaceted approach, China Resources Pharmaceutical Group Ltd. continues to play a crucial role in shaping the future of healthcare in China, navigating challenges and opportunities with the acuity expected of an industry leader.

Intrinsic Value
16.01 HKD
Undervaluation 68%
Intrinsic Value
Price
C
Back to Top